PL1996556T3 - Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA - Google Patents

Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA

Info

Publication number
PL1996556T3
PL1996556T3 PL06830303T PL06830303T PL1996556T3 PL 1996556 T3 PL1996556 T3 PL 1996556T3 PL 06830303 T PL06830303 T PL 06830303T PL 06830303 T PL06830303 T PL 06830303T PL 1996556 T3 PL1996556 T3 PL 1996556T3
Authority
PL
Poland
Prior art keywords
receptor complex
benzimidazole derivatives
gabaa receptor
modulating
compounds
Prior art date
Application number
PL06830303T
Other languages
English (en)
Polish (pl)
Inventor
Janus S Larsen
Lene Teuber
Philip K Ahring
Elsebet Östergaard Nielsen
Naheed Mirza
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of PL1996556T3 publication Critical patent/PL1996556T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06830303T 2005-12-05 2006-12-04 Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA PL1996556T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200501719 2005-12-05
US74253505P 2005-12-06 2005-12-06
DKPA200601326 2006-10-12
US85129106P 2006-10-13 2006-10-13
PCT/EP2006/069237 WO2007065864A1 (en) 2005-12-05 2006-12-04 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EP06830303A EP1996556B1 (en) 2005-12-05 2006-12-04 Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
PL1996556T3 true PL1996556T3 (pl) 2010-05-31

Family

ID=37873123

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06830303T PL1996556T3 (pl) 2005-12-05 2006-12-04 Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA

Country Status (14)

Country Link
US (1) US7923464B2 (enExample)
EP (1) EP1996556B1 (enExample)
JP (1) JP2009518292A (enExample)
KR (1) KR20080077620A (enExample)
AT (1) ATE449077T1 (enExample)
AU (1) AU2006324046A1 (enExample)
CA (1) CA2632395A1 (enExample)
DE (1) DE602006010602D1 (enExample)
DK (1) DK1996556T3 (enExample)
ES (1) ES2335438T3 (enExample)
IL (1) IL189974A0 (enExample)
NO (1) NO20083045L (enExample)
PL (1) PL1996556T3 (enExample)
WO (1) WO2007065864A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
AU2008345696A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Benzimidazole compounds
CN102036952A (zh) * 2008-04-16 2011-04-27 比奥里波克斯公司 用作药物的双芳基化合物
US20110301192A1 (en) * 2008-10-01 2011-12-08 The Regents Of The University Of California Inhibitors of Cyclin Kinase Inhibitor p21
WO2010055125A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055127A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
CA2218493C (en) 1995-04-21 2005-02-22 Neurosearch A/S Benzimidazole compounds and their use as modulators of the gabaa receptor complex
AU726447B2 (en) * 1996-10-21 2000-11-09 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators
CN1275127A (zh) 1997-10-10 2000-11-29 神经研究公司 苯并咪唑化合物、含该化合物的药物组合物及其应用
BR0011823A (pt) * 1999-06-22 2002-03-19 Neurosearch As Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
AU2002221566A1 (en) 2000-12-20 2002-07-01 Neurosearch A/S Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
MXPA05010449A (es) 2003-04-03 2006-05-31 Neurosearch As Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa.
US7335777B2 (en) * 2003-04-03 2008-02-26 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
BRPI0413746A (pt) * 2003-08-21 2006-10-24 Osi Pharm Inc composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
EP1678144A1 (en) 2003-10-23 2006-07-12 Akzo Nobel N.V. 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX
CA2589770A1 (en) * 2004-12-01 2006-06-08 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
CA2604516A1 (en) * 2005-04-13 2006-10-19 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EP1874758A1 (en) * 2005-04-19 2008-01-09 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途

Also Published As

Publication number Publication date
US20090048321A1 (en) 2009-02-19
KR20080077620A (ko) 2008-08-25
DE602006010602D1 (de) 2009-12-31
ES2335438T3 (es) 2010-03-26
DK1996556T3 (da) 2010-04-06
JP2009518292A (ja) 2009-05-07
EP1996556A1 (en) 2008-12-03
ATE449077T1 (de) 2009-12-15
WO2007065864A1 (en) 2007-06-14
CA2632395A1 (en) 2007-06-14
US7923464B2 (en) 2011-04-12
NO20083045L (no) 2008-09-04
IL189974A0 (en) 2008-08-07
AU2006324046A1 (en) 2007-06-14
EP1996556B1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
JO2645B1 (en) Vehicles
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
PL1979355T3 (pl) Pochodne spiro imidazoli jako modulatory PPAR
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2009003981A (es) Agentes moduladores del receptor de calcio.
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
MX2010005704A (es) Derivados de cromano como modulares del trpv3.
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
TW200611695A (en) Pyrrolopyridine derivatives
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MX357504B (es) Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2004087690A3 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
NO20075793L (no) Benzimidazolderivater og deres anvendelse for modulering av GABAA - reseptorkomplekset
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
UA104861C2 (uk) Похідні хроману як модулятори trpv3
ATE386519T1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands